Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70:338–51.

Article  PubMed  Google Scholar 

Wollenberg A, Christen-Zäch S, Taieb A, et al. ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. J Eur Acad Dermatol Venereol. 2020;34:2717–44.

Article  PubMed  CAS  Google Scholar 

Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Prim. 2018;4:1.

Article  PubMed  Google Scholar 

Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017. Br J Dermatol. 2021;184:304–9.

Article  PubMed  CAS  Google Scholar 

Drucker AM, Wang AR, Li WQ, Sevetson E, Block JK, Qureshi AA. The burden of atopic dermatitis: summary of a report for the National Eczema Association. J Invest Dermatol. 2017;137:26–30.

Article  PubMed  CAS  Google Scholar 

Simpson EL, Guttman-Yassky E, Margolis DJ, et al. Association of inadequately controlled disease and disease severity with patient-reported disease burden in adults with atopic dermatitis. JAMA Dermatol. 2018;154:903–12.

Article  PubMed  PubMed Central  Google Scholar 

Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139:583–90.

Article  PubMed  CAS  Google Scholar 

Na CH, Chung J, Simpson EL. Quality of life and disease impact of atopic dermatitis and psoriasis on children and their families. Children (Basel, Switzerland). 2019;6:133.

PubMed  PubMed Central  Google Scholar 

Bacci ED, Correll JR, Pierce EJ, et al. Burden of adult atopic dermatitis and unmet needs with existing therapies. J Dermatol Treat. 2023;34:2202288.

Article  Google Scholar 

Eyerich K, Gooderham MJ, Silvestre JF, et al. Real-world clinical, psychosocial and economic burden of atopic dermatitis: Results from a multicountry study. J Eur Acad Dermatol Venereol. 2024;38:340–53.

Article  PubMed  Google Scholar 

Silverberg JI, Gelfand JM, Margolis DJ, et al. Patient burden and quality of life in atopic dermatitis in US adults: a population-based cross-sectional study. Ann Allergy Asthma Immunol. 2018;121:340–7.

Article  PubMed  Google Scholar 

Simpson EL, Bieber T, Eckert L, et al. Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. J Am Acad Dermatol. 2016;74:491–8.

Article  PubMed  CAS  Google Scholar 

Brunner PM, Silverberg JI, Guttman-Yassky E, et al. Increasing comorbidities suggest that atopic dermatitis is a systemic disorder. J Investig Dermatol. 2017;137:18–25.

Article  PubMed  CAS  Google Scholar 

Eckert L, Gupta S, Amand C, Gadkari A, Mahajan P, Gelfand JM. The burden of atopic dermatitis in US adults: Health care resource utilization data from the 2013 National Health and Wellness Survey. J Am Acad Dermatol. 2018;78:54-61.e1.

Article  PubMed  Google Scholar 

Manjelievskaia J, Boytsov N, Brouillette MA, et al. The direct and indirect costs of adult atopic dermatitis. J Manag Care Spec Pharm. 2021;27:1416–25.

PubMed  Google Scholar 

Katoh N, Ohya Y, Ikeda M, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int. 2020;69:356–69.

Article  PubMed  CAS  Google Scholar 

Girolomoni G, Busà VM. Flare management in atopic dermatitis: from definition to treatment. Ther Adv Chronic Dis. 2022;13:20406223211066730.

Article  PubMed  PubMed Central  Google Scholar 

Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I—systemic therapy. J Eur Acad Dermatol Venereol. 2022;36:1409–31.

Article  PubMed  CAS  Google Scholar 

Chu DK, Schneider L, Asiniwasis RN, et al. Atopic dermatitis (eczema) guidelines: 2023 American Academy of Allergy, Asthma and Immunology/American College of Allergy, Asthma and Immunology Joint Task Force on Practice Parameters GRADE- and Institute of Medicine-based recommendations. Ann Allergy Asthma Immunol. 2024;132:274–312.

Article  PubMed  Google Scholar 

Sidbury R, Alikhan A, Bercovitch L, et al. Guidelines of care for the management of atopic dermatitis in adults with topical therapies. J Am Acad Dermatol. 2023;89:e1–20.

Article  PubMed  CAS  Google Scholar 

Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema—part II: non-systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36:1904–26.

Article  PubMed  CAS  Google Scholar 

Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Engl J Med. 2016;375:2335–48.

Article  PubMed  CAS  Google Scholar 

Silverberg JI, Guttman-Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate-to-severe atopic dermatitis. N Engl J Med. 2023;388:1080–91.

Article  PubMed  CAS  Google Scholar 

Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–49.

Article  PubMed  CAS  Google Scholar 

Simpson EL, Lacour JP, Spelman L, et al. Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials. Br J Dermatol. 2020;183:242–55.

Article  PubMed  CAS  Google Scholar 

Guttman-Yassky E, Teixeira HD, Simpson EL, et al. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021;397:2151–68.

Article  PubMed  CAS  Google Scholar 

Simpson EL, Sinclair R, Forman S, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396:255–66.

Article  PubMed  CAS  Google Scholar 

Dupixent [package insert]. Tarrytown, NY: Regeneron Pharmaceuticals, Inc.; 2024.

Ebglyss [summary of product characteristics]. Amsterdam, The Netherlands: European Medicines Agency; 2023.

Adbry [package insert]. Madison, NJ: Leo Pharma, Inc.; 2023.

Olumiant [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.

Olumiant [summary of product characteristics]. European Medicines Agency; 2023.

Silverberg JI, Wollenberg A, Reich A, et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet. 2024;404:445–60.

Article  PubMed  CAS  Google Scholar 

Nemluvio [package insert]. Dallas, TX: Galderma Laboratories; 2024.

Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184:450–63.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Wu JJ, Lafeuille MH, Emond B, et al. Real-world effectiveness of newly initiated systemic therapy for atopic dermatitis in the United States: a claims database analysis. Adv Ther. 2022;39:4157–68.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Facheris P, Jeffery J, Del Duca E, Guttman-Yassky E. The translational revolution in atopic dermatitis: the paradigm shift from pathogenesis to treatment. Cell Mol Immunol. 2023;20:448–74.

Article  PubMed  PubMed Central